Loading
A phase 1/2 trial in triple-negative breast cancer, run by Harbin Medical University, not yet recruiting.
Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer is a phase 1/2, interventional study registered as NCT07161791 by Harbin Medical University, with a registry enrolment figure of 12 participants, started 2025-09-15 and due to reach its primary completion in 2026-12-31. Interventions recorded: Camrelizumab Combined With Pirfenidone and Chemotherapy. Conditions listed: Breast Cancer; Triple Negative Breast Cancer (TNBC). Triple-negative eligibility wording from the registry: "* Histologically confirmed recurrent/metastatic TNBC (ER-negative: IHC ER \<1%; PR-negative: IHC PR \<1%; HER2-negative: IHC -/+, or IHC ++ but FISH/CISH negative), with at least one measurable lesion per RECIST v1". No results are recorded here; the registry entry is the source.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.